Total worldwide sales revenues for epigenomics markets were $930.6 million in 2009, and are expected to increase to more than $6 billion in 2014, a compound annual growth rate (CAGR) of 45%.
The largest epigenomic market segments in 2009 were pharmaceuticals and research tools. Pharmaceuticals revenues will increase from $590 million in 2009 to nearly $4 billion in 2014, a compound annual growth rate (CAGR) of 46%.
Sales of epigenomics-based in-vitro diagnostics will experience high growth. This market segment was worth $27 million in 2009 and will increase at a 114% compound annual growth rate (CAGR) to reach a value of $1.2 billion in 2014.
STUDY GOALS AND OBJECTIVES
BCC’s goal for this study was to examine the status of commercial epigenomics technologies and products and assess their worldwide growth potential over a 5-year period from 2009 to 2014. We analyzed the four important market segments for epigenomics: research tools, diagnostics, therapeutics, and assays for cellular therapies.
Our objective was to present a comprehensive discussion of where the state-of-the-art is in epigenomics technologies and the current and future commercial potential for these key market segments. We also wanted to study current large-scale epigenome funding projects as well as the industry competitive and patent dynamics.
REASONS FOR DOING THE STUDY
Epigenomics is a fast-growing biology field that is rapidly commercializing. Epigenomics research tools and products enable discovery of novel diagnostic biomarkers and drug targets. We previously examined the epigenetics market in 2007. Since that time, the FDA approved several epigenetic drugs for treating non-Hodgkin’s lymphomas and myelodysplastic syndromes. In the past 2 years, several epigenetic-based in-vitro diagnostics tests have been launched in the United States and Europe for early colon cancer detection. A significant number of additional drug candidates and diagnostics tests are in the clinical pipeline and ready to be commercialized during our forecast horizon.
We are interested in determining the particular diseases for which epigenomic-based diagnostics products will be used and the market and growth potential for these applications. We are also interested in understanding the scope of the future market potential for epigenetic drugs, including DNA methylase inhibitors and histone deacetylase inhibitors.
It is particularly timely to examine the epigenomics industry in 2010 given the changes in the industry and the increasing importance of gene regulation beyond DNA sequence.
We have compiled a study of important epigenomics technologies used in the four major applications of research tools, diagnostics, therapeutics, and cellular therapies. We define and describe the fundamental epigenomic technologies, the market driving forces, product types, main market applications, key companies, strategic alliances and acquisitions, future global market potential and product sales forecasts for the period 2009 through 2014.
We analyze in detail the clinical pipelines for both epigenetic-based diagnostics and therapeutics.
This study will be of particular interest to the molecular diagnostics industry, pharmaceutical manufacturers, biotechnology companies, and life science research tools companies. It will also be of interest to companies involved in drug and/or biomarker discovery programs; manufacturers of microarrays or next generation sequencing systems, high-grade antibodies, restriction enzymes or primers; bioinformatics developers, and cancer researchers and clinicians.
SCOPE OF REPORT
The study scope includes the major epigenomics technologies that are now, or likely to become, commercialized within the next 5 years. We examine the products flowing from these technologies, market segments into which these products are sold, and we forecast product sales for the period 2009 through 2014. We describe factors that are driving growth in these markets. Competitive dynamics and key trends in each of the market segments are discussed.
We examine the strategies of successful companies, strategic alliances, and the impact that large-scale epigenomic projects have on the industry. We profile the major companies in the industry.
The scope of our analysis includes DNA methylation and histone acetylation and methylation technologies; and the important market segments within research tools, diagnostics, therapies, and cellular therapeutics. We are particularly interested in cancer indications, which comprise the bulk of the diagnostics and therapies markets.
Both primary and secondary research methodologies were used in preparing this market research report. Included is an analysis of each of the four key market segments that will be commercially important during the next 5 years: research tools, cancer diagnostics, cancer therapeutics, and cellular therapies. We examine each the important product types within these market segments, and estimate the current and future sales from this perspective. We provide sales revenue for 2008, 2009, and forecast growth through 2014 for each of these segments.
For each of the market segments, we present market information for the important products and technologies. For drugs and diagnostics, we present market information by indication and by technology. For research tools, we present market information by technology format and product type.
BCC surveyed life-science companies and research institutions to obtain data for this study. Included were research tools firms, diagnostics firms, drug firms, epigenetic biotechnology companies, and leading epigenomic research institutions. We also spoke with users of in-vitro personalized medicine devices. In addition, we compiled data from secondary sources, including industry, trade, and government.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers.
The information developed in this report, is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.